Message from the Director, RMTI Research
Welcome to the Recanati/Miller Transplantation Institute at The Mount Sinai Health System in New York City.
Established in 2001, the Recanati/Miller Transplantation Institute (RMTI) continues to pursue an increasing number of urgently-needed clinical research projects. It is our intent to enroll all of our patients in an appropriate clinical study, as this best assures the continued advancements of the field as well as the best outcome for our patients.
Under the leadership of Peter S. Heeger, MD, Director of the Clinical Research Program, and Sander S. Florman, MD, Director of the RMTI, the Institute’s clinical research team supports the research efforts of Mount Sinai’s Transplantation Services. We offer the newest and most innovative approaches to organ transplantation, whether the originating cause is kidney disease, liver disease, infectious disease, cancer or other illness.
The focus of our research program is to explore new and promising therapies to improve the quality of life for patients before and after transplant and to increase the life expectancy of all transplant recipients.
As a groundbreaking transplant center, we have designed, led and participated in many important national and international research projects. Our dedicated and highly trained research coordinators are responsible for more than 35 research projects. Our research coordinators are assisting and collaborating with faculty from other departments within Icahn School of Medicine, including the departments of Medicine, Infectious Diseases, Endocrinology, Psychiatry, Pediatrics, and Medical and Surgical Oncology.
Our research projects focus on the following areas:
• Organ transplantation in HIV-positive patients
• Hepatitis B and hepatitis C in adults and children
• Acute liver failure in adults and children
• Gene therapy for liver transplantation
• Diagnosis and treatment of non-alcoholic steatohepatitis
• Determining which patients are at highest risk of developing transplant failure and designing new ways to preventing organ rejection following kidney or liver transplantation
Our reputation in the field of clinical research is built on our commitment to protecting the rights and welfare of human subjects, rapid regulatory start-up, enrollment of appropriate patients, following and monitoring patients per protocol, and providing excellent and timely data.
The overall goals of our clinical research program include:
• Enhancing RMTI’s working relationship with the National Institutes of Health, drug manufacturers, and other major medical institutions
• Assisting RMTI faculty in offering our patients the newest and most innovative approaches to organ transplantation
• Developing expertise in the field and using that knowledge to devise better intervention strategies to limit disease progression and graft loss.
If you would like more information on our research program or our clinical trials, please call us at 212-241-0255 or send us an e-mail. We welcome your interest and questions.
Peter S. Heeger, MD
Director, RMTI Research